The European Parliament has given final approval to a landmark regulation that will ease the path for crops developed using new genomic techniques (NGTs), marking a decisive shift in the bloc’s approach to agricultural biotechnology. Under the new framework, plants modified with tools such as CRISPR-Cas9 to carry small, targeted genetic changes will no longer be subject to the stringent authorisation and labelling rules that govern traditional genetically modified organisms. Instead, many will be treated as equivalent to conventionally bred varieties, meaning they can be sold without mandatory GMO labelling. The rules, expected to take effect by mid-2028, are designed to accelerate the development of crops with enhanced drought tolerance, disease resistance, or reduced pesticide needs — traits European policymakers increasingly view as vital for climate adaptation and food sovereignty.

The vote in Strasbourg, which followed three years of tense negotiations, exposed deep divisions across the continent. Proponents, including many scientists and farming unions, argue that NGTs differ fundamentally from first-generation GMOs because they edit a plant’s own genome without inserting foreign DNA. Critics, however, denounce the move as a backdoor approval of genetic modification that strips consumers of transparency and risks concentrating power in the hands of a few agribusiness giants. A particularly sharp dispute, highlighted by analysts in Berlin, concerns patents: the new legislation does not resolve whether gene-edited plants can be patented, leaving open the possibility that small breeders and farmers could face costly licensing fees and legal battles similar to those that plagued earlier GMO traits.

While Europe refines its regulatory architecture, sub-Saharan Africa is confronting a more immediate biological threat to staple crops with a different technological toolkit. The parasitic weed Striga hermonthica, which latches onto the roots of maize and sorghum, continues to cause severe yield losses across the region, including in Ghana, where cereals are central to food security. In response, the International Atomic Energy Agency and the Food and Agriculture Organization have launched a joint initiative that uses radiation to induce beneficial mutations in crop seeds, accelerating natural evolution to produce Striga-resistant varieties. This nuclear-derived technique avoids the transgenic label and the associated regulatory and public-acceptance obstacles that have long stalled the adoption of genetically modified crops in many African nations.

Viewed from London or Washington, the parallel developments expose a widening global divergence in biotechnology governance. Europe’s calibrated embrace of NGTs reflects a pragmatic turn driven by climate pressures and a desire to keep pace with competitors in the Americas and Asia, where gene-edited crops are already advancing. Yet the unresolved patent question and the enduring legacy of anti-GMO sentiment could slow commercial rollout. Meanwhile, Africa’s reliance on less precise but politically uncontroversial methods such as mutation breeding illustrates how regulatory environments shape technological choices. As climate stress intensifies, the gap between regions able to deploy cutting-edge gene editing and those constrained to older tools may deepen, carrying profound consequences for global food equity and trade.